The National Health Fund (NFZ) spent PLN 7.1bn (€1.7bn) on drug reimbursement in the first seven months of 2018, an increase of 4.5% compared with the same period of 2017. The amount represents 57% of the NFZ’s projected drug reimbursement spend in 2018 as a whole.
Of the total sum spent by the NFZ in January-July 2018, spending on the reimbursement of products available upon prescription in the pharmacy channel – medicines, foods for particular nutritional uses, and medical devices – amounted to PLN 4.9bn (€1.2bn), an increase of 3.5%. The figure represents 59% of the annual plan.
Reimbursement of hospital drugs via drug programmes amounted to PLN 1.78bn (€414m) and was 6.5% higher than a year ago. The amount represents 53.1% of the full-year plan.
Reimbursement of chemotherapy drugs slightly exceeded PLN 372m (€87m) in January-July 2018, up 8% year on year. The amount represents 54.2% of the annual plan.
|NFZ spending on drug reimbursement (PLN m), change (%, y-o-y) and its share (%) in planned annual budget (PLN m), Jan-Jul 2018|
|PMR based on NFZ, 2018|
|Specification||Jan-Jul 2017||Jan-Jul 2018||Change||Planned budget for 2018||Spending in Jan-Jul 2018 as a percentage of planned budget|
|Medicines, foods for particular nutritional uses and medical devices available upon prescription in the pharmacy channel||4,759.9||4,926.6||3.5%||8,375.3||58.8%|
|Reimbursement via drug programmes||1,668.9||1,776.9||6.5%||3,348.9||53.1%|